AFFILIATIONS
1 UCL Cancer Institute, University College London, London, United Kingdom
2 Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, Cornell University, New York, United States
3 Johns Hopkins University School of Medicine, Baltimore, United States
4 Emory University School of Medicine, Atlanta, United States
5 City of Hope National Medical Center, Duarte, United States
6 City of Hope National Medical Center, Duarte, United States
7 Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
8 University of Nebraska Medical Center, Omaha, United States
9 Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, United States
10 UC Davis Medical Center, Sacramento, United States
11 Centro de Investigación Farmaceutica Especializada de Occidente, Guadalajara, Mexico
12 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia
13 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia
14 Saint-Louis Hospital, AP-HP, University of Paris, Paris, France
15 Transplant Infectious Disease Service, University Hospital of Geneva, Geneva, Switzerland
16 University Hospital Zurich, Zurich, Switzerland
17 AiCuris Anti-infective Cures AG, Wuppertal, Germany
18 AiCuris Anti-infective Cures AG, Wuppertal, Germany
19 AiCuris Anti-infective Cures AG, Wuppertal, Germany
20 AiCuris Anti-infective Cures AG, Wuppertal, Germany
21 AiCuris Anti-infective Cures AG, Wuppertal, Germany
22 AiCuris Anti-infective Cures AG, Wuppertal, Germany
23 Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, Cornell University, New York, United States
24 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background: Pritelivir is a novel oral helicase-primase inhibitor active against herpes simplex virus type 1 and 2 (HSV-1 and HSV-2), including strains resistant to acyclovir (ACV) and foscarnet. In the pivotal, phase 3, randomized comparator-controlled PRIOH-1 clinical trial, pritelivir demonstrated superior lesion healing up to 28 days of therapy, which further increased up to 42 days, and a favorable safety and tolerability profile compared with investigator’s choice treatment (ICT), in immunocompromised (IC) patients with refractory HSV infection with/without laboratory confirmed ACV resistance (R±R). This subgroup analysis presents efficacy data from the patients with hematological malignancies, including those who underwent hematopoietic cell transplantation (HCT).
Methods: In this randomized (1:1), controlled, open-label trial, 101 IC patients (≥18 years) with ACV R±R HSV mucocutaneous infection received oral pritelivir (100 mg daily; 400 mg loading dose) or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod) for up to 28 days, extended up to 42 days, if lesions were improving. A post hoc analysis was performed on patients with underlying hematological malignancy to estimate the treatment effect in this subgroup on lesion healing up to 28 days of therapy, and up to 42 days of therapy.
Results: Of 101 patients enrolled, 47 had an underlying hematological malignancy, resulting in 18 on the pritelivir arm and 29 on ICT. 83% (39/47) had undergone HCT and/or solid organ transplant, and 94% (44/47) had more than one immunocompromised condition. The mean age of patients was 55.9 years (range 19 to 84) and 61.7% were female. Refractory HSV without clinical improvement after at least 7 days of antiviral treatment was reported in 55.3% of these patients, and laboratory confirmed ACV resistance in 44.7%. HSV-1 and HSV-2 were identified in 55.3% and 40.4%, respectively. HSV subtype was not specified in 1 subject (2.1%), and not detected at baseline in 1 subject (2.1%), with inclusion based on clinical diagnosis. The mean (SD) maximum lesion length was 35.8 (37.19) mm, and 53.2% were oral vs. 46.8% genital. Completion of treatment was higher with pritelivir (88.9% [16/18]) than ICT (48.3% [14/29]). The majority (82.8% [24/29]) of the patients in the ICT group were treated with foscarnet. In this post hoc statistical analysis of patients with hematological malignancies, complete lesion healing was achieved by 50% (9/18) of the patients in the pritelivir arm vs. 34.5% (10/29) in the ICT arm with an adjusted treatment difference of 15.4%, up to 28 days of treatment (95% CI, -13.8, 44.5; p=0.306). Further improvement was observed up to 42 days, with 77.8% (14/18) of pritelivir-treated patients achieving complete lesion healing vs. 44.8% (13/29) with ICT, adjusted treatment difference of 32.5% (95% CI, 6.4, 58.7; p=0.030). In the overall trial population, pritelivir was associated with less frequent treatment-emergent adverse events (TEAEs) compared with ICT, and fewer renal/urinary (5.9% vs. 26%), electrolyte abnormalities (2% vs. 16%), and hematological adverse events (9.8% vs. 28%). The drug-related TEAE discontinuation rate was lower for pritelivir (2.0%) compared with ICT (20.0%).
Conclusions
In this post hoc analysis of the hematologic malignancies subgroup, there was a positive treatment difference with pritelivir compared with ICT, consistent with the overall phase 3 results, with a nominal statistically significant effect at up to 42 days of treatment. These findings support pritelivir as a promising oral agent to address the unmet needs of refractory HSV infections in IC patients with hematological malignancies.
DISCLOSURES
Karl S. Peggs: AiCuris Anti-infective Cures AG - Research Funding